Eltrombopag added to standard immunosuppression for aplastic anemia

New England Journal of Medicine

Volumn 376, Issue 16, 2017, Pages 1540-1550

  Townsley, Danielle M ^a   Scheinberg, Phillip ^c   Winkler, Thomas ^a   Desmond, Ronan ^a   Dumitriu, Bogdan ^a   Rios, Olga ^a   Weinstein, Barbara ^a   Valdez, Janet ^a   Lotter, Jennifer ^a   Feng, Xingmin ^a   Desierto, Marie ^a   Leuva, Harshraj ^a   Bevans, Margaret ^b   Wu, Colin ^a   Larochelle, Andre ^a   Calvo, Katherine R ^b   Dunbar, Cynthia E ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ECULIZUMAB; ELTROMBOPAG; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY; BENZOIC ACID DERIVATIVE; CD34 ANTIGEN; HEMATOLOGIC AGENT; HYDRAZINE DERIVATIVE; LYMPHOCYTE ANTIBODY; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CD34 SELECTION; CELL COUNTING; CELL PROLIFERATION; CHILD; CLONAL EVOLUTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RASH; RELAPSE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; AGONISTS; ANEMIA, APLASTIC; CELL COUNT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; BENZOATES; CELL COUNT; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC AGENTS; HUMANS; HYDRAZINES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; YOUNG ADULT;

EID: 85018476496     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1613878     Document Type: Article

References (31)

1. Camitta BM. Criteria for severe aplastic anaemia. Lancet 1988; 1: 303-4.
2. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-19.
3. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991; 324: 1297-304.
4. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85: 3058-65.
5. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-8.
6. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003; 289: 1130-5.
7. Scheinberg P, Townsley D, Dumitriu B, et al. Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood 2014; 124: 2820-3.
8. Marmont AM, Bacigalupo A, Van Lint MT, et al. Treatment of severe aplastic anemia with high-dose methylprednisolone and antilymphocyte globulin. Prog Clin Biol Res 1984; 148: 271-87.
9. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony- stimulating factor in children with acquired aplastic anemia. Blood 2000; 96: 2049-54.
10. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133: 606-11.
11. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009; 94: 348-54.
12. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood 1996; 88: 1983-91.
13. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009; 144: 206-16.
14. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr 2008; 153: 814-9.
15. Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med 1999; 130: 193-201.
16. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012; 367: 11-9.
17. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014; 123: 1818-25.
18. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 1997; 94: 5320-5.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
20. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120: 1185-96.
21. Huntsman HD, Bat T, Cheng H, et al. Human hematopoietic stem cells from mobilized peripheral blood can be purified based on CD49f integrin expression. Blood 2015; 126: 1631-3.
22. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129-35.
23. Dumitriu B, Feng X, Townsley DM, et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood 2015; 125: 706-9.
24. Deng Z, Glousker G, Molczan A, et al. Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal- Hreidarsson syndrome. Proc Natl Acad Sci U S A 2013; 110: E3408-E3416.
25. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood 2014; 124: 2775-83.
26. Geddis AE. Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 2011; 57: 199-203.
27. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996; 87: 2162-70.
28. Feng X, Scheinberg P, Wu CO, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011; 96: 602-6.
29. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068-71.
30. de Bruin AM, Voermans C, Nolte MA. Impact of interferon-γ on hematopoiesis. Blood 2014; 124: 2479-86.
31. Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol 2015; 2(10): e417-e426.